Compare Inovio Pharmaceuticals Inc (INO) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while GraniteShares 2x Long NVDA Daily ETF trades at $31.29. The key difference: GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | NVDL | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.87 | $43.02 |
52-Week Low | $1.05 | $21.76 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $30.51 with a 0.76% daily gain. The technical outlook is bearish with moving averages signaling selling pressure, while oscillators remain neutral. Recent news highlights the fund's volatility, including a 12% single-day drop on June 5, 2026, and a 67% decline in early 2025, underscoring the risks of daily leverage reset mechanics.
The outlook for NVDL is heavily tied to NVIDIA's performance and AI sector momentum. While the ETF has delivered strong returns year-to-date (up 12.66% as of June 8, 2026), its leveraged structure amplifies both gains and losses. Key risks include NVIDIA's earnings volatility, broader semiconductor market swings, and the compounding effect of daily resets during downtrends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
